Key result
DG-041 antagonized the pro-aggregatory effects of sulprostone and PGE2 on human platelets, maintaining efficacy in the presence of aspirin and a P2Y12 antagonist.
Why the study?
Does DG-041 inhibit EP3-mediated platelet aggregation in human platelet-rich plasma or whole blood?
Population
Human platelet-rich plasma or whole blood
Design
Preclinical
Authors
Loading...
Supports further preclinical development of DG-041 for EP3 inhibition; leaves open clinical antithrombotic efficacy beyond dual antiplatelet therapy.
Does DG-041 inhibit EP3-mediated platelet aggregation in human platelet-rich plasma or whole blood?
DG-041 effectively inhibits EP3-mediated platelet aggregation in vitro, suggesting potential as a novel antithrombotic agent.
Heptinstall et al. (2008) studied atherothrombosis. DG-041 was evaluated on platelet aggregation and function. DG-041 antagonized the pro-aggregatory effects of sulprostone and PGE2 on human platelets, maintaining efficacy in the presence of aspirin and a P2Y12 antagonist.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: